Details:
According to the agreement, Richter is responsible for the development of the denosumab, Products (to conduct both Phase 1 and Phase 3 global clinical studies) and will supply finished commercial Products for the US market.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 09, 2021